Objective:

To evaluate the effectiveness of Chinese Herbal Medicine (CHM) on leukopenia/neutropenia induced by chemotherapy in adults with colorectal cancer (CRC).

Methods:

Eight electronic databases were searched from their inception to June 2020. Randomized controlled trials with clarified sequence generation were qualified. Two reviewers independently conducted the screening and data extraction. Methodological quality was assessed using the Risk of Bias tool. RevMan 5.4 was applied to the meta-analysis.

Results:

Twenty-seven studies involving 1867 participants were qualified, of which 26 were included in the quantitative synthesis. Meta-analysis showed that CHM significantly reduced the incidence of leukopenia induced by chemotherapy (RR = 0.69; 95% CI 0.59-0.82), as well as the grade 3/4 leukopenia (RR = 0.71; 95% CI 0.55-0.90). Meanwhile,CHM decreased the occurrence of neutropenia (RR = 0.52, 95% CI 0.35-0.77), especially for the grades 3/4 neutropenia (RR = 0.42, 95% CI 0.27-0.64). Twenty-six of the included studies focused on the adverse events related to CHM.

Conclusion:

CHM may relieve neutropenia/leukopenia induced by chemotherapy in adults with colorectal cancer.

中文翻译：

---

中草药治疗成人结直肠癌化疗所致白细胞减少/中性粒细胞减少的有效性：系统评价和荟萃分析

客观的：

评估中草药 (CHM) 对成人结直肠癌 (CRC) 化疗引起的白细胞减少/中性粒细胞减少的疗效。

方法：

检索了从成立到 2020 年 6 月的八个电子数据库。具有明确序列生成的随机对照试验合格。两名评价员独立进行筛选和数据提取。使用偏倚风险工具评估方法学质量。RevMan 5.4 被应用于荟萃分析。

结果：

涉及 1867 名参与者的 27 项研究合格，其中 26 项纳入定量合成。荟萃分析显示，CHM 显着降低了化疗引起的白细胞减少症（RR = 0.69；95% CI 0.59-0.82）以及 3/4 级白细胞减少症（RR = 0.71；95% CI 0.55-0.90）的发生率。同时，CHM降低了中性粒细胞减少症的发生率（RR = 0.52，95% CI 0.35-0.77），尤其是3/4级中性粒细胞减少症（RR = 0.42，95% CI 0.27-0.64）。纳入的研究中有 26 项关注与 CHM 相关的不良事件。

结论：

CHM 可以缓解成人结直肠癌化疗引起的中性粒细胞减少症/白细胞减少症。